TB-500 (Thymosin Beta-4) 10mg Preclinical data suggest potential in

Preclinical data suggest potential in autoimmune disorder research

Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂ (amidated C-terminus)

Key Research Areas

is an 11-amino-acid linear synthetic peptide derived from the helix B region of erythropoietin (EPO)

CJC-1295 no DAC significantly reduced visceral and subcutaneous fat mass

TB-500 (Thymosin Beta-4) 10mg Preclinical data suggest potential inOverview TB 500 is the synthetic, acetylated active fragment (1723) of Thymosin Beta 4, represented by the sequence Ac LKKTETQ. This research peptide is widely studied in laboratory and preclinical environments for its involvement in actin regulation, cellular migration, angiogenesis, tissue remodeling, and inflammatory pathway modulation. Due to its defined active region and smaller molecular size, TB 500 is frequently utilized in in vitro and animal